Intralesional cidofovir for the management of refractory cutaneous verrucae: a review of applications and opportunities.
Ther Adv Infect Dis
; 10: 20499361231165862, 2023.
Article
en En
| MEDLINE
| ID: mdl-37056449
ABSTRACT
Viral warts - manifestations of cutaneous infection by human papilloma virus - can be a significant physical and emotional burden for patients when common treatments fail, particularly for individuals who are immunocompromised or with multiple lesions. Cidofovir, an antiviral agent typically used for the treatment of cytomegalovirus infection, has emerged as an alternative treatment option for viral warts when administered topically or intralesionally. In this review, we highlight the scientific rationale, published evidence, and practical clinical uses of intralesional cidofovir for the management of cutaneous warts as well as ongoing questions requiring further research and exploration of this emerging therapy for refractory verrucae.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Ther Adv Infect Dis
Año:
2023
Tipo del documento:
Article
País de afiliación:
Estados Unidos